Genetic-analysis technology company CuraGen ( CRGN) reported a narrower loss and exceeded analysts' sales expectations in the third quarter, sending its shares higher Thursday.

The company reported a $15.9 million loss, amounting to 29 cents a share, compared with a loss of $22.5 million, or 43 cents a share, a year ago. Analysts were expecting the company to lose 34 cents a share.

Revenue reached $9.86 million, up from $5.2 million in the year-ago period and ahead of the consensus estimate of $8.77 million.

The stock rose 6.4% to $3.98.

CuraGen's majority-owned subsidiary 454 Life Sciences showed strong third-quarter sales, driven by its Genome Sequencer 20 system and record demand for its chemical reagents.

"We look forward to the anticipated launch of the Genome Sequencer FLX next year, as we believe the flexibility of this instrument will continue to expand the use of genomic sequencing to a broader range of researchers and drive revenues at 454 Life Sciences," said Frank Armstrong, CuraGen's president and CEO.

Additionally, CuraGen improved its full-year guidance by $5 million and now expects a loss of $60 million to $65 million.

More from Stocks

Dow Futures Tank as Trade War Fears Grip Wall Street

Dow Futures Tank as Trade War Fears Grip Wall Street

Why GE's Stock Has Fallen 9% in the Last 30 Days

Why GE's Stock Has Fallen 9% in the Last 30 Days

5 Stock Picks Under $10 for Millennials

5 Stock Picks Under $10 for Millennials

3 Complicated Investing Strategies Millennials Love

3 Complicated Investing Strategies Millennials Love

Tyson Foods CEO: We Aren't Done Making Deals

Tyson Foods CEO: We Aren't Done Making Deals